Huapont Life Sciences Co Ltd (002004) - Net Assets
Based on the latest financial reports, Huapont Life Sciences Co Ltd (002004) has net assets worth CN¥16.10 Billion CNY (≈ $2.36 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥29.24 Billion ≈ $4.28 Billion USD) and total liabilities (CN¥13.15 Billion ≈ $1.92 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Huapont Life Sciences Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥16.10 Billion |
| % of Total Assets | 55.05% |
| Annual Growth Rate | 25.23% |
| 5-Year Change | 9.46% |
| 10-Year Change | 48.63% |
| Growth Volatility | 45.15 |
Huapont Life Sciences Co Ltd - Net Assets Trend (2001–2024)
This chart illustrates how Huapont Life Sciences Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Huapont Life Sciences Co Ltd assets under control for the complete picture of this company's asset base.
Annual Net Assets for Huapont Life Sciences Co Ltd (2001–2024)
The table below shows the annual net assets of Huapont Life Sciences Co Ltd from 2001 to 2024. For live valuation and market cap data, see 002004 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥15.47 Billion ≈ $2.26 Billion |
-6.70% |
| 2023-12-31 | CN¥16.58 Billion ≈ $2.43 Billion |
+0.21% |
| 2022-12-31 | CN¥16.55 Billion ≈ $2.42 Billion |
+4.59% |
| 2021-12-31 | CN¥15.82 Billion ≈ $2.32 Billion |
+11.93% |
| 2020-12-31 | CN¥14.14 Billion ≈ $2.07 Billion |
+6.74% |
| 2019-12-31 | CN¥13.24 Billion ≈ $1.94 Billion |
+3.88% |
| 2018-12-31 | CN¥12.75 Billion ≈ $1.87 Billion |
-4.12% |
| 2017-12-31 | CN¥13.30 Billion ≈ $1.95 Billion |
+24.22% |
| 2016-12-31 | CN¥10.70 Billion ≈ $1.57 Billion |
+2.82% |
| 2015-12-31 | CN¥10.41 Billion ≈ $1.52 Billion |
+81.62% |
| 2014-12-31 | CN¥5.73 Billion ≈ $838.76 Million |
+42.86% |
| 2013-12-31 | CN¥4.01 Billion ≈ $587.13 Million |
+35.69% |
| 2012-12-31 | CN¥2.96 Billion ≈ $432.69 Million |
+14.35% |
| 2011-12-31 | CN¥2.59 Billion ≈ $378.40 Million |
+149.66% |
| 2010-12-31 | CN¥1.04 Billion ≈ $151.57 Million |
+15.43% |
| 2009-12-31 | CN¥897.32 Million ≈ $131.31 Million |
+10.23% |
| 2008-12-31 | CN¥814.07 Million ≈ $119.12 Million |
+11.38% |
| 2007-12-31 | CN¥730.86 Million ≈ $106.95 Million |
+39.77% |
| 2006-12-31 | CN¥522.90 Million ≈ $76.52 Million |
+18.66% |
| 2005-12-31 | CN¥440.68 Million ≈ $64.49 Million |
+9.72% |
| 2004-12-31 | CN¥401.64 Million ≈ $58.77 Million |
+175.58% |
| 2003-12-31 | CN¥145.74 Million ≈ $21.33 Million |
+42.64% |
| 2002-12-31 | CN¥102.18 Million ≈ $14.95 Million |
+16.80% |
| 2001-12-31 | CN¥87.48 Million ≈ $12.80 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Huapont Life Sciences Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8652.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.60 Billion | 17.11% |
| Common Stock | CN¥1.98 Billion | 21.20% |
| Other Comprehensive Income | CN¥1.01 Billion | 10.82% |
| Other Components | CN¥4.75 Billion | 50.87% |
| Total Equity | CN¥9.34 Billion | 100.00% |
Huapont Life Sciences Co Ltd Competitors by Market Cap
The table below lists competitors of Huapont Life Sciences Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ERAMET EO 305 ADR 1/10
F:ER70
|
$1.44 Billion |
|
Dole PLC
NYSE:DOLE
|
$1.44 Billion |
|
Eurocommercial Properties N.V.
AS:ECMPA
|
$1.44 Billion |
|
Jiangsu Zijin Rural Commercial Bank Co Ltd
SHG:601860
|
$1.44 Billion |
|
Xinyu Iron & Steel Co Ltd
SHG:600782
|
$1.44 Billion |
|
FAP Agri Tbk PT
JK:FAPA
|
$1.44 Billion |
|
Amore Group
KO:002790
|
$1.44 Billion |
|
Res Robex Inc
V:RBX
|
$1.44 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Huapont Life Sciences Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,105,176,600 to 9,337,058,000, a change of -768,118,600 (-7.6%).
- Net loss of 298,989,912 reduced equity.
- Dividend payments of 754,366,728 reduced retained earnings.
- Other comprehensive income increased equity by 1,009,823,000.
- Other factors decreased equity by 724,584,960.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-298.99 Million | -3.2% |
| Dividends Paid | CN¥754.37 Million | -8.08% |
| Other Comprehensive Income | CN¥1.01 Billion | +10.82% |
| Other Changes | CN¥-724.58 Million | -7.76% |
| Total Change | CN¥- | -7.60% |
Book Value vs Market Value Analysis
This analysis compares Huapont Life Sciences Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.05x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 56.39x to 1.05x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | CN¥0.09 | CN¥4.97 | x |
| 2002-12-31 | CN¥0.10 | CN¥4.97 | x |
| 2003-12-31 | CN¥0.15 | CN¥4.97 | x |
| 2004-12-31 | CN¥0.38 | CN¥4.97 | x |
| 2005-12-31 | CN¥0.43 | CN¥4.97 | x |
| 2006-12-31 | CN¥0.46 | CN¥4.97 | x |
| 2007-12-31 | CN¥0.67 | CN¥4.97 | x |
| 2008-12-31 | CN¥0.76 | CN¥4.97 | x |
| 2009-12-31 | CN¥0.85 | CN¥4.97 | x |
| 2010-12-31 | CN¥0.99 | CN¥4.97 | x |
| 2011-12-31 | CN¥2.41 | CN¥4.97 | x |
| 2012-12-31 | CN¥2.13 | CN¥4.97 | x |
| 2013-12-31 | CN¥2.66 | CN¥4.97 | x |
| 2014-12-31 | CN¥3.51 | CN¥4.97 | x |
| 2015-12-31 | CN¥5.09 | CN¥4.97 | x |
| 2016-12-31 | CN¥4.76 | CN¥4.97 | x |
| 2017-12-31 | CN¥4.69 | CN¥4.97 | x |
| 2018-12-31 | CN¥4.47 | CN¥4.97 | x |
| 2019-12-31 | CN¥4.67 | CN¥4.97 | x |
| 2020-12-31 | CN¥4.86 | CN¥4.97 | x |
| 2021-12-31 | CN¥5.11 | CN¥4.97 | x |
| 2022-12-31 | CN¥5.15 | CN¥4.97 | x |
| 2023-12-31 | CN¥5.10 | CN¥4.97 | x |
| 2024-12-31 | CN¥4.73 | CN¥4.97 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Huapont Life Sciences Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.56%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 3.15x
- Recent ROE (-3.20%) is below the historical average (12.46%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 35.56% | 17.87% | 1.30x | 1.52x | CN¥22.36 Million |
| 2002 | 37.05% | 18.63% | 0.97x | 2.06x | CN¥27.23 Million |
| 2003 | 27.61% | 16.60% | 1.07x | 1.56x | CN¥25.46 Million |
| 2004 | 12.59% | 17.48% | 0.57x | 1.27x | CN¥9.81 Million |
| 2005 | 12.18% | 19.20% | 0.57x | 1.11x | CN¥9.41 Million |
| 2006 | 14.23% | 22.28% | 0.38x | 1.70x | CN¥19.08 Million |
| 2007 | 30.83% | 41.93% | 0.45x | 1.63x | CN¥139.49 Million |
| 2008 | 11.79% | 15.70% | 0.50x | 1.51x | CN¥13.51 Million |
| 2009 | 15.24% | 23.45% | 0.48x | 1.36x | CN¥43.89 Million |
| 2010 | 13.54% | 24.40% | 0.40x | 1.39x | CN¥34.49 Million |
| 2011 | 12.76% | 48.54% | 0.15x | 1.75x | CN¥65.97 Million |
| 2012 | 12.39% | 8.57% | 0.65x | 2.21x | CN¥64.12 Million |
| 2013 | 7.97% | 6.78% | 0.58x | 2.01x | CN¥-77.04 Million |
| 2014 | 7.70% | 8.82% | 0.36x | 2.43x | CN¥-128.39 Million |
| 2015 | 6.69% | 10.31% | 0.31x | 2.07x | CN¥-315.69 Million |
| 2016 | 5.88% | 7.99% | 0.29x | 2.51x | CN¥-397.66 Million |
| 2017 | 5.33% | 5.51% | 0.32x | 3.06x | CN¥-443.51 Million |
| 2018 | 5.59% | 4.79% | 0.40x | 2.93x | CN¥-400.05 Million |
| 2019 | 6.64% | 6.15% | 0.38x | 2.85x | CN¥-313.87 Million |
| 2020 | 6.77% | 5.99% | 0.39x | 2.93x | CN¥-311.22 Million |
| 2021 | 6.61% | 5.37% | 0.41x | 2.97x | CN¥-343.13 Million |
| 2022 | 4.25% | 3.28% | 0.44x | 2.95x | CN¥-585.71 Million |
| 2023 | 2.99% | 2.61% | 0.38x | 3.04x | CN¥-708.40 Million |
| 2024 | -3.20% | -2.56% | 0.40x | 3.15x | CN¥-1.23 Billion |
Industry Comparison
This section compares Huapont Life Sciences Co Ltd's net assets metrics with peer companies in the Agricultural Inputs industry.
Industry Context
- Industry: Agricultural Inputs
- Average net assets among peers: $3,388,904,979
- Average return on equity (ROE) among peers: -6.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Huapont Life Sciences Co Ltd (002004) | CN¥16.10 Billion | 35.56% | 0.82x | $1.44 Billion |
| Hubei Yihua Chemical Industry Co Ltd (000422) | $492.29 Million | 7.61% | 0.82x | $2.69 Billion |
| Nanjing Red Sun Co Ltd (000525) | $722.87 Million | 4.05% | 2.23x | $1.05 Billion |
| ADAMA Ltd (000553) | $1.12 Billion | 2.13% | 0.80x | $2.17 Billion |
| Grand Industrial Holding Co Ltd (000626) | $2.88 Billion | -13.11% | 1.48x | $693.17 Million |
| Sichuan Meifeng Chemical Industry Co Ltd (000731) | $2.76 Billion | -8.85% | 0.64x | $581.45 Million |
| Qinghai Salt Lake Industry Co.Ltd (000792) | $22.24 Billion | -18.70% | 2.71x | $30.42 Billion |
| Asia Potash International Investment Guangzhou Co Ltd (000893) | $330.55 Million | 1.85% | 1.50x | $7.31 Billion |
| Hubei Xinyangfeng Fertilizer Co Ltd (000902) | $402.47 Million | -12.08% | 2.18x | $2.80 Billion |
| Sichuan Lutianhua Co Ltd (000912) | $2.67 Billion | 17.08% | 0.75x | $1.12 Billion |
| Guangxi Hechi Chemical Co Ltd (000953) | $271.96 Million | -46.60% | 2.89x | $374.49 Million |
About Huapont Life Sciences Co Ltd
Huapont Life Sciences Co.,Ltd. engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally. The company is involved in the production and sale of pharmaceutical preparations and raw materials. It also offers medicines for skin, tuberculosis, anti-infection, respiratory, anti-tumor, and cardiovascular, as well as health management… Read more